Low Neutralizing Activities to the Omicron Subvariants BN.1 and XBB.1.5 of Sera From the Individuals Vaccinated With a BA.4/5-Containing Bivalent mRNA Vaccine
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
The continuous emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants has provided insights for updating current coronavirus disease 2019 (COVID-19) vaccines. We examined the neutralizing activity of Abs induced by a BA.4/5-containing bivalent mRNA vaccine against Omicron subvariants BN.1 and XBB.1.5. We recruited 40 individuals who had received a monovalent COVID-19 booster dose after a primary series of COVID-19 vaccinations and will be vaccinated with a BA.4/5-containing bivalent vaccine. Sera were collected before vaccination, one month after, and three months after a bivalent booster. Neutralizing Ab (nAb) titers were measured against ancestral SARS-CoV-2 and Omicron subvariants BA.5, BN.1, and XBB.1.5. BA.4/5-containing bivalent vaccination significantly boosted nAb levels against both ancestral SARS-CoV-2 and Omicron subvariants. Participants with a history of SARS-CoV-2 infection had higher nAb titers against all examined strains than the infection-naïve group. NAb titers against BN.1 and XBB.1.5 were lower than those against the ancestral SARS-CoV-2 and BA.5 strains. These results suggest that COVID-19 vaccinations specifically targeting emerging Omicron subvariants, such as XBB.1.5, may be required to ensure better protection against SARS-CoV-2 infection, especially in high-risk groups.
Abstract
The continuous emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants has provided insights for updating current coronavirus disease 2019 (COVID-19) vaccines. We examined the neutralizing activity of Abs induced by a BA.4/5-containing bivalent mRNA vaccine against Omicron subvariants BN.1 and XBB.1.5. We recruited 40 individuals who had received a monovalent COVID-19 booster dose after a primary series of COVID-19 vaccinations and will be vaccinated with a BA.4/5-containing bivalent vaccine. Sera were collected before vaccination, one month after, and three months after a bivalent booster. Neutralizing Ab (nAb) titers were measured against ancestral SARS-CoV-2 and Omicron subvariants BA.5, BN.1, and XBB.1.5. BA.4/5-containing bivalent vaccination significantly boosted nAb levels against both ancestral SARS-CoV-2 and Omicron subvariants. Participants with a history of SARS-CoV-2 infection had higher nAb titers against all examined strains than the infection-naïve group. NAb titers against BN.1 and XBB.1.5 were lower than those against the ancestral SARS-CoV-2 and BA.5 strains. These results suggest that COVID-19 vaccinations specifically targeting emerging Omicron subvariants, such as XBB.1.5, may be required to ensure better protection against SARS-CoV-2 infection, especially in high-risk groups.
참고문헌 (30)
- "Tracking SARS-CoV-2 variants"[URL]
- Liu L, "Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2", Nature, 602, pp.676~681 (2022)
- Collier AY, "Immunogenicity of BA. 5 bivalent mRNA vaccine boosters", N Engl J Med, 388, pp.565~567 (2023)
- Chalkias S, "A bivalent Omicron-containing booster vaccine against COVID-19", N Engl J Med, 387, pp.1279~1291 (2022)
- "Press release" (2023)[URL]
- "Press release" (2023)[URL]
- "TAG-VE statement on Omicron sublineages BQ.1 and XBB"[URL]
- "COVID data tracker: variant proportions"[URL]
- "Statement on the antigen composition of COVID-19 vaccines"[URL]
- "Updated COVID-19 vaccines for use in the United States beginning in fall 2023"[URL]
- Sun D, "Development and qualification of a fast, high-throughput and robust imaging-based neutralization assay for respiratory syncytial virus", J Immunol Methods, 494, pp.113054~ (2021)
- Whiteman MC, "Virus reduction neutralization test : a single-cell imaging high-throughput virus neutralization assay for dengue", Am J Trop Med Hyg, 99, pp.1430~1439 (2018)
- Grist NR, "Diagnostic methods in clinical virology" (1974), J. B. Lippincott
- "Lineage list"[URL]
- Cao Y, "Imprinted SARSCoV-2 humoral immunity induces convergent Omicron RBD evolution", Nature, 614, pp.521~529 (2023)
- Liu Y, "Inactivated vaccineelicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants", Nat Commun, 14, pp.2179~ (2023)
- Liu S, "Sera from breakthrough infections with SARS-CoV-2 BA. 5 or BF. 7 showed lower neutralization activity against XBB. 1. 5 and CH. 1. 1", Emerg Microbes Infect, 12, pp.2225638~ (2023)
- Wang Q, "Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants", Cell, 186, pp.279~286 (2023)
- Miller J, "Substantial neutralization escape by SARS-CoV-2 Omicron variants BQ. 1. 1 and XBB. 1", N Engl J Med, 388, pp.662~664 (2023)
- Zou J, "Neutralization of BA. 4–BA. 5, BA. 4. 6, BA. 2. 75. 2, BQ. 1. 1, and XBB. 1 with bivalent vaccine", N Engl J Med, 388, pp.854~857 (2023)
- Davis-Gardner ME, "Neutralization against BA. 2. 75. 2, BQ. 1. 1, and XBB from mRNA bivalent booster", N Engl J Med, 388, pp.183~185 (2023)
- Korea Disease Control and Prevention Agency, "Neutralizing antibody against omicron subvariants (BA.1, BA.1.1, and BA.2)", Public Health Wkly Rep, 15, pp.1460~1462 (2022)
- Kurhade C, "Low neutralization of SARS-CoV-2Omicron BA. 2. 75. 2, BQ. 1. 1 and XBB. 1 by parental mRNA vaccine or a BA. 5 bivalent booster", Nat Med, 29, pp.344~347 (2023)
- "Waning immunity against XBB.1.5 following bivalent mRNA boosters" (2023)[URL]
- Wang Q, "SARS-CoV-2neutralising antibodies after bivalent versus monovalent booster", Lancet Infect Dis, 23, pp.527~528 (2023)
- Branche AR, "Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines : the phase 2randomized open-label COVAIL trial", Nat Med, 29, pp.2334~2346 (2023)
- Cohen KW, "Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2infection with persisting antibody responses and memory B and T cells", Cell Rep Med, 2, pp.100354~ (2021)
- Traut CC, "Bivalent mRNA vaccine-elicited SARS-CoV-2 specific T cells recognise the omicron XBB sublineage", Lancet Microbe, 4, pp.e388~ (2023)
- 박계명, "Omicron Subvariants, Including BA.4 and BA.5, Substantially Preserve T Cell Epitopes of Ancestral SARS-CoV-2", Immune Network, 22(4), pp.1~3 (2022), 대한면역학회[DOI]
- Choi SJ, "T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant", Cell Mol Immunol, 19, pp.447~448 (2022)